GOS to Reduce Symptom Severity in IBS

NACompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

October 26, 2021

Primary Completion Date

August 6, 2024

Study Completion Date

August 6, 2024

Conditions
Irritable Bowel SyndromeIrritable Bowel Syndrome - ConstipationIrritable Bowel Syndrome - DiarrhoeaIrritable Bowel Syndrome - Mixed
Interventions
DIETARY_SUPPLEMENT

Galacto-oligosaccharides (GOS)

An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a prebiotic supplement is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.

DIETARY_SUPPLEMENT

Maltodextrine

An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a placebo is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.

Trial Locations (9)

3000

University Hospital Leuven location Gasthuisberg, Leuven

5223GZ

Jeroen Bosch Ziekenhuis, Gastroenterology department, 's-Hertogenbosch

8934AD

Medisch Centrum Leeuwarden (MCL), Leeuwarden

6716 RP

Ziekenhuis Gelderse Vallei, Afdeling Maag-Darm-Leverziekten, Ede

LS9 7TF

Leeds Teaching Hospital NHS Trust in association with the University of Leeds, Leeds

DH1 5TW

County Durham &Darlington NHS Foundation trust, University Hospital of North Durham, Durham

E1 2AJ

Barts Health NHS Trust, Wingate Clinical Trials Facility, London

M23 9LT

Manchester University NHS Foundation Trust, Wythenshawe Hospital, Neurogastroenterology Unit, Manchester

NE4 6BE

NIHR National Patient Recruitment Centre Newcastle, Newcastle upon Tyne

All Listed Sponsors
collaborator

CR2O B.V.

UNKNOWN

lead

Clasado

INDUSTRY

NCT05157061 - GOS to Reduce Symptom Severity in IBS | Biotech Hunter | Biotech Hunter